JPWO2020247974A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247974A5 JPWO2020247974A5 JP2021571671A JP2021571671A JPWO2020247974A5 JP WO2020247974 A5 JPWO2020247974 A5 JP WO2020247974A5 JP 2021571671 A JP2021571671 A JP 2021571671A JP 2021571671 A JP2021571671 A JP 2021571671A JP WO2020247974 A5 JPWO2020247974 A5 JP WO2020247974A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cytotoxic agent
- linked
- optionally
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025077691A JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856468P | 2019-06-03 | 2019-06-03 | |
| US62/856,468 | 2019-06-03 | ||
| PCT/US2020/070113 WO2020247974A1 (en) | 2019-06-03 | 2020-06-03 | Methods and compositions for treating cancer with collagen binding drug carriers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077691A Division JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022535816A JP2022535816A (ja) | 2022-08-10 |
| JP2022535816A5 JP2022535816A5 (https=) | 2023-06-13 |
| JPWO2020247974A5 true JPWO2020247974A5 (https=) | 2023-06-13 |
| JP7680375B2 JP7680375B2 (ja) | 2025-05-20 |
Family
ID=73652058
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021571671A Active JP7680375B2 (ja) | 2019-06-03 | 2020-06-03 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025077691A Pending JP2025121986A (ja) | 2019-06-03 | 2025-05-08 | コラーゲン結合薬物担体を用いてがんを処置するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220298225A1 (https=) |
| EP (1) | EP3976111A4 (https=) |
| JP (2) | JP7680375B2 (https=) |
| CN (1) | CN114173822B (https=) |
| AU (1) | AU2020289485A1 (https=) |
| BR (1) | BR112021024438A2 (https=) |
| CA (1) | CA3144535A1 (https=) |
| MX (1) | MX2021014932A (https=) |
| WO (1) | WO2020247974A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2024177006A1 (https=) * | 2023-02-20 | 2024-08-29 | ||
| US12605394B2 (en) | 2024-07-25 | 2026-04-21 | Visionary Assets, Llc | Compositions containing cannabinoid nanoparticles |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5962406A (en) | 1991-10-25 | 1999-10-05 | Immunex Corporation | Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5871986A (en) | 1994-09-23 | 1999-02-16 | The General Hospital Corporation | Use of a baculovirus to express and exogenous gene in a mammalian cell |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101808751B1 (ko) * | 2009-11-13 | 2017-12-13 | 그리폴스 테라퓨틱스 인코포레이티드 | 폰 빌레브란트 인자(ｖＷＦ)-함유 제제, 및 그와 관련된 방법, 키트 및 용도 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2012112690A2 (en) * | 2011-02-16 | 2012-08-23 | Fabius Biotechnology | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains |
| JP2014022858A (ja) | 2012-07-17 | 2014-02-03 | Murata Mfg Co Ltd | 電力増幅器 |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| JP6508785B2 (ja) * | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| EP3094650A2 (en) * | 2014-01-13 | 2016-11-23 | Pieris Pharmaceuticals GmbH | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2016033331A1 (en) * | 2014-08-28 | 2016-03-03 | Bioatla, Llc | Conditionally active chimeric antigen receptors for modified t-cells |
| WO2016054107A1 (en) * | 2014-09-29 | 2016-04-07 | Counterpoint Biomedica Llc | Targeting of pharmaceutical agents to pathologic areas using bifunctional fusion polymers |
| WO2017106656A1 (en) * | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
| AU2019366956B2 (en) * | 2018-10-23 | 2025-10-30 | Dragonfly Therapeutics, Inc. | Heterodimeric Fc-fused proteins |
-
2020
- 2020-06-03 BR BR112021024438A patent/BR112021024438A2/pt unknown
- 2020-06-03 CN CN202080055104.6A patent/CN114173822B/zh active Active
- 2020-06-03 CA CA3144535A patent/CA3144535A1/en active Pending
- 2020-06-03 WO PCT/US2020/070113 patent/WO2020247974A1/en not_active Ceased
- 2020-06-03 JP JP2021571671A patent/JP7680375B2/ja active Active
- 2020-06-03 EP EP20818032.3A patent/EP3976111A4/en active Pending
- 2020-06-03 AU AU2020289485A patent/AU2020289485A1/en active Pending
- 2020-06-03 US US17/596,118 patent/US20220298225A1/en active Pending
- 2020-06-03 MX MX2021014932A patent/MX2021014932A/es unknown
-
2025
- 2025-05-08 JP JP2025077691A patent/JP2025121986A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Curnis et al. | NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
| JP2023041829A (ja) | セリンプロテアーゼ分子および療法 | |
| Halin et al. | Tumor‐targeting properties of antibody–vascular endothelial growth factor fusion proteins | |
| JP2025121986A5 (https=) | ||
| JP2009519925A (ja) | 治療および診断におけるプレターゲッティングに適したアネキシン誘導体 | |
| WO2004021861A2 (en) | Targeted release | |
| Frank et al. | Strategies for enhancing antibody delivery to the brain | |
| JP2020524141A5 (https=) | ||
| McGonigle et al. | Neuropilin-1 drives tumor-specific uptake of chlorotoxin | |
| JPWO2021016640A5 (https=) | ||
| TW202227139A (zh) | Fap活化之血清延長半衰期治療結合物 | |
| SK12782001A3 (sk) | Protilátkové a chemokínové konštrukty a ich použitie pri liečbe autoimunitných chorôb | |
| CA3177566A1 (en) | Tnf.alpha. immunoconjugate therapy for the treatment of brain tumors | |
| JPWO2020247974A5 (https=) | ||
| RIPPMANN et al. | Fusion of the tissue factor extracellular domain to a tumour stroma specific single-chain fragment variable antibody results in an antigen-specific coagulation-promoting molecule | |
| Corti | Strategies for improving the anti-neoplastic activity of TNF by tumor targeting | |
| Rybak et al. | Ribonucleases and immunoRNases as anticancer drugs | |
| CN111499762A (zh) | 一种包含PDGFRβ特异性亲和体和TNFα的融合蛋白及其用途 | |
| AU753303B2 (en) | Enhancement of intracellular delivery and tissue targeting of drugs and genes | |
| Martinez-Torro et al. | Lymphocyte infiltration and antitumoral effect promoted by cytotoxic inflammatory proteins formulated as self-assembling, protein-only nanoparticles | |
| Hao et al. | ‘Renovation of old drugs’–can peptide drug conjugates lead the post-ADC era? | |
| Dreischalück et al. | Vascular infarction by subcutaneous application of tissue factor targeted to tumor vessels with NGR-peptides: activity and toxicity profile | |
| AU2011287552B2 (en) | Antibodies against 6-sulfo-LacNAc-positive human dendritic cells, and their use | |
| KR20250164808A (ko) | Gprc5d에 결합하는 나노바디 및 이의 용도 | |
| JPWO2022236292A5 (https=) |